EU Decision Time For Albireo’s Rare Liver Disease Drug

Odevixibat, which could become the first drug approved for treating progressive familial intrahepatic cholestasis in children, is up for an opinion from the European Medicines Agency.

Liver
PFIC is rare and devastating pediatric liver disease • Source: Shutterstock

More from Product Reviews

More from Pink Sheet